{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:46:27Z","timestamp":1790113587112,"version":"4.0.1"},"reference-count":193,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic sclerosis (SSc) is a heterogeneous disease characterized by autoimmunity, vasculopathy, and fibrosis which affects the skin and internal organs. One key aspect of SSc vasculopathy is pulmonary arterial hypertension (SSc-PAH) which represents a leading cause of morbidity and mortality in patients with SSc. The pathogenesis of pulmonary hypertension is complex, with multiple vascular cell types, inflammation, and intracellular signaling pathways contributing to vascular pathology and remodeling. In this review, we focus on shared molecular features of pulmonary hypertension and those which make SSc-PAH a unique entity. We highlight advances in the understanding of the clinical and translational science pertinent to this disease. We first review clinical presentations and phenotypes, pathology, and novel biomarkers, and then highlight relevant animal models, key cellular and molecular pathways in pathogenesis, and explore emerging treatment strategies in SSc-PAH.<\/jats:p>","DOI":"10.3390\/ijms25094728","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T08:18:27Z","timestamp":1714119507000},"page":"4728","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again"],"prefix":"10.3390","volume":"25","author":[{"given":"Milan","family":"Bahi","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 695, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 695, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaochan","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 695, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4873-2628","authenticated-orcid":false,"given":"Benjamin D.","family":"Korman","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 695, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1264906","DOI":"10.3389\/fmed.2023.1264906","article-title":"Clinical features of pulmonary arterial hypertension associated with systemic sclerosis","volume":"10","author":"Tuhy","year":"2023","journal-title":"Front. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","article-title":"Incidence and prevalence of systemic sclerosis globally: A comprehensive systematic review and meta-analysis","volume":"60","author":"Bairkdar","year":"2021","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/rccm.202204-0731OC","article-title":"Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry","volume":"207","author":"Hassan","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"210053","DOI":"10.1183\/16000617.0053-2021","article-title":"Pulmonary hypertension phenotypes in patients with systemic sclerosis","volume":"30","author":"Haque","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_9","first-page":"73","article-title":"Pulmonary hypertension: Types and treatments","volume":"11","author":"McLaughlin","year":"2015","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fca-2020-0238","article-title":"Prevalence and prognostic significance of heart failure with preserved ejection fraction in systemic sclerosis","volume":"18","author":"Rei","year":"2022","journal-title":"Future Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e12117","DOI":"10.1002\/pul2.12117","article-title":"Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity","volume":"12","author":"Sangani","year":"2022","journal-title":"Pulm. Circ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.chest.2023.03.029","article-title":"Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension","volume":"164","author":"Yang","year":"2023","journal-title":"Chest"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102713","DOI":"10.1016\/j.autrev.2020.102713","article-title":"The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis","volume":"20","author":"Homs","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/rheumatology\/35.10.989","article-title":"Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients","volume":"35","author":"Koh","year":"1996","journal-title":"Br. J. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.41669","article-title":"Long-Term Outcomes in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary Arterial Hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.953","article-title":"Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis","volume":"195","author":"Tuder","year":"2001","journal-title":"J. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1164\/rccm.201507-1508LE","article-title":"Intrapulmonary Bronchopulmonary Anastomoses and Plexiform Lesions in Idiopathic Pulmonary Arterial Hypertension","volume":"193","author":"Galambos","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09031936.00081009","article-title":"Beyond arterial remodelling: Pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension","volume":"35","author":"Dorfmuller","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1183\/09031936.00106008","article-title":"Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: A distinctive vasculopathy","volume":"34","author":"Overbeek","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","article-title":"Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases","volume":"38","author":"Dorfmuller","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"604615","DOI":"10.1155\/2010\/604615","article-title":"Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension","volume":"2010","author":"Overbeek","year":"2010","journal-title":"Int. J. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.112.000008","article-title":"Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension","volume":"6","author":"Tedford","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1161\/CIRCULATIONAHA.117.033147","article-title":"Right Ventricular Myofilament Functional Differences in Humans with Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension","volume":"137","author":"Hsu","year":"2018","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41467-023-44645-6","article-title":"Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCRESAHA.123.323299","article-title":"Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics","volume":"134","author":"Li","year":"2024","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1801899","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1161\/CIRCRESAHA.121.319971","article-title":"The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure","volume":"130","author":"Boucherat","year":"2022","journal-title":"Circ. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Happe, C., Kurakula, K., Sun, X.Q., da Silva Goncalves Bos, D., Rol, N., Guignabert, C., Tu, L., Schalij, I., Wiesmeijer, K.C., and Tura-Ceide, O. (2020). The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient. Cells, 9.","DOI":"10.3390\/cells9061422"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1161\/01.RES.88.1.e2","article-title":"Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension","volume":"88","author":"Yeager","year":"2001","journal-title":"Circ. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Graf","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1164\/rccm.201508-1678OC","article-title":"Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension","volume":"194","author":"Hemnes","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-3-030-92616-8_10","article-title":"The Immunogenetics of Systemic Sclerosis","volume":"1367","author":"Unlu","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1136\/annrheumdis-2012-201755","article-title":"TGFbeta receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: Results from a multicentre EUSTAR study of European Caucasian patients","volume":"71","author":"Koumakis","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102602","DOI":"10.1016\/j.autrev.2020.102602","article-title":"Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)","volume":"19","author":"Jiang","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fmed.2018.00175","article-title":"Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data","volume":"5","author":"Hickey","year":"2018","journal-title":"Front. Med."},{"key":"ref_39","first-page":"106","article-title":"Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry","volume":"35","author":"Chung","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.autrev.2018.06.009","article-title":"Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma\u2014A review","volume":"17","author":"Nunes","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/S2665-9913(22)00224-7","article-title":"Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts","volume":"4","author":"Liem","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/annrheumdis-2021-221354","article-title":"Anti-ANP32A antibodies in systemic sclerosis","volume":"81","author":"Wallwork","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/rheumatology\/keac594","article-title":"Autoimmune activation and hypersensitization of the AT1 and ETA receptors contributes to vascular injury in scleroderma renal crisis","volume":"62","author":"Hegner","year":"2023","journal-title":"Rheumatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2002591","DOI":"10.1183\/13993003.02591-2020","article-title":"Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: Machine learning on proteomics from the DETECT cohort","volume":"57","author":"Bauer","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/ard-2022-223237","article-title":"Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis","volume":"82","author":"Sanges","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13075-018-1679-8","article-title":"Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis","volume":"20","author":"Rice","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.chest.2022.08.2230","article-title":"Metabolomic Profiles Differentiate Scleroderma-PAH from Idiopathic PAH and Correspond with Worsened Functional Capacity","volume":"163","author":"Alotaibi","year":"2023","journal-title":"Chest"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"L617","DOI":"10.1152\/ajplung.00177.2023","article-title":"Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension","volume":"325","author":"Simpson","year":"2023","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"Affandi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/art.40534","article-title":"CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis","volume":"70","author":"Hesselstrand","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-020-02218-8","article-title":"Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension","volume":"22","author":"Guggino","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-022-02734-9","article-title":"Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension","volume":"24","author":"Kolstad","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/rheumatology\/kez035","article-title":"Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: A multicentre study","volume":"58","author":"Vadasz","year":"2019","journal-title":"Rheumatology"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Lammi, M.R., Kolstad, K.D., Saketkoo, L.A., Khatri, A., Utz, P.J., Steen, V.D., and Chung, L. (2023). Endothelial Biomarkers of Systemic Sclerosis-Associated Pulmonary Hypertension. Arthritis Care Res., 1\u20137.","DOI":"10.1002\/acr.25180"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13075-015-0712-4","article-title":"Biomarkers of pulmonary hypertension in patients with scleroderma: A case-control study","volume":"17","author":"McMahan","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/rheumatology\/keab300","article-title":"Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension","volume":"61","author":"Wuttge","year":"2021","journal-title":"Rheumatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bph.15444","article-title":"Animal models of pulmonary hypertension: Getting to the heart of the problem","volume":"179","author":"Dignam","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.chest.2017.10.007","article-title":"Fifty Years of Monocrotaline-Induced Pulmonary Hypertension: What Has It Meant to the Field?","volume":"152","author":"Hill","year":"2017","journal-title":"Chest"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"H243","DOI":"10.1152\/ajpheart.00728.2013","article-title":"Temporal hemodynamic and histological progression in Sugen5416\/hypoxia\/normoxia-exposed pulmonary arterial hypertensive rats","volume":"306","author":"Toba","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/CIRCULATIONAHA.119.040629","article-title":"Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation","volume":"140","author":"Tian","year":"2019","journal-title":"Circulation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.autrev.2018.06.013","article-title":"Recent advances in mouse models for systemic sclerosis","volume":"17","author":"Yue","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.0801414105","article-title":"Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2\/AP-1","volume":"105","author":"Eferl","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/art.41309","article-title":"Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension","volume":"72","author":"Bell","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ame2.12220","article-title":"Experimental animal models of pulmonary hypertension: Development and challenges","volume":"5","author":"Wu","year":"2022","journal-title":"Anim. Models Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00012313","article-title":"Reversibility of the monocrotaline pulmonary hypertension rat model","volume":"42","author":"Ruiter","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4939-8597-5_18","article-title":"Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration","volume":"1816","author":"Sassi","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0026-2862(89)90017-4","article-title":"Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats","volume":"38","author":"Wilson","year":"1989","journal-title":"Microvasc. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1164\/rccm.202006-2169OC","article-title":"Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning","volume":"203","author":"Hong","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI10259","article-title":"Inhibition of VEGF receptors causes lung cell apoptosis and emphysema","volume":"106","author":"Kasahara","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1096\/fj.00-0343com","article-title":"Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension","volume":"15","author":"Kasahara","year":"2001","journal-title":"FASEB J."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Katz, M.G., Fargnoli, A.S., Gubara, S.M., Bisserier, M., Sassi, Y., Bridges, C.R., Hajjar, R.J., and Hadri, L. (2019). The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats. J. Vis. Exp., e59050.","DOI":"10.3791\/59050-v"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/678508","article-title":"The Sugen 5416\/hypoxia mouse model of pulmonary hypertension revisited: Long-term follow-up","volume":"4","author":"Vitali","year":"2014","journal-title":"Pulm. Circ."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.107.736801","article-title":"Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension","volume":"118","author":"Hong","year":"2008","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1161\/CIRCRESAHA.121.320541","article-title":"Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension","volume":"132","author":"Wang","year":"2023","journal-title":"Circ. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.vph.2012.12.001","article-title":"The Fra-2 transgenic mouse model of systemic sclerosis","volume":"58","author":"Maurer","year":"2013","journal-title":"Vasc. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/annrheumdis-2011-200940","article-title":"Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis","volume":"71","author":"Maurer","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1165\/rcmb.2016-0200OC","article-title":"Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis","volume":"57","author":"Looney","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1128\/MCB.01278-08","article-title":"Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin","volume":"29","author":"Asano","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2353\/ajpath.2010.090593","article-title":"Endothelial Fli1 deficiency impairs vascular homeostasis: A role in scleroderma vasculopathy","volume":"176","author":"Asano","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/ncomms6797","article-title":"Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis","volume":"5","author":"Noda","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/art.40903","article-title":"Selective Sexual Dimorphisms in Musculoskeletal and Cardiopulmonary Pathologic Manifestations and Mortality Incidence in the Tumor Necrosis Factor-Transgenic Mouse Model of Rheumatoid Arthritis","volume":"71","author":"Bell","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_83","first-page":"3222","article-title":"TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype","volume":"74","author":"Duemmel","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_84","unstructured":"Rangel-Moreno, J., Garcia-Hernandez, M., Xu, Q., and Korman, B. (2023). TNF-mediated Pulmonary Hypertension Is Marked by Aberrant Bone Morphogenic Protein (BMP) and Integrin\/Basement Membrane Ligand-Receptor Signaling. Arthritis Rheumatol., 75."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2003957","DOI":"10.1183\/13993003.03957-2020","article-title":"Endothelial cells in the pathogenesis of pulmonary arterial hypertension","volume":"58","author":"Evans","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_86","first-page":"693","article-title":"Loss of PPARgamma in endothelial cells leads to impaired angiogenesis","volume":"129","author":"Akinrinade","year":"2016","journal-title":"J. Cell Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1164\/rccm.201402-0322OC","article-title":"Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor\/CD74 Complex","volume":"192","author":"Tu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","article-title":"BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis","volume":"4","author":"Evans","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/ars.2020.8169","article-title":"Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension","volume":"34","author":"Gorelova","year":"2021","journal-title":"Antioxid. Redox Signal."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Patnaik, E., Lyons, M., Tran, K., and Pattanaik, D. (2023). Endothelial Dysfunction in Systemic Sclerosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814385"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"103559","DOI":"10.1016\/j.drudis.2023.103559","article-title":"Pulmonary artery smooth muscle cell phenotypic switching: A key event in the early stage of pulmonary artery hypertension","volume":"28","author":"Ma","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/CIRCRESAHA.117.312111","article-title":"Distinct Cellular Mechanisms Underlie Smooth Muscle Turnover in Vascular Development and Repair","volume":"122","author":"Roostalu","year":"2018","journal-title":"Circ. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1016\/j.cell.2021.06.024","article-title":"Fibroblasts: Origins, definitions, and functions in health and disease","volume":"184","author":"Plikus","year":"2021","journal-title":"Cell"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.cell.2022.03.011","article-title":"LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma","volume":"185","author":"Gur","year":"2022","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/annrheumdis-2018-214865","article-title":"Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease","volume":"78","author":"Valenzi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1038\/s41467-021-24607-6","article-title":"Myofibroblast transcriptome indicates SFRP2(hi) fibroblast progenitors in systemic sclerosis skin","volume":"12","author":"Tabib","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1150028","DOI":"10.3389\/fphys.2023.1150028","article-title":"Pericytes: The lung-forgotten cell type","volume":"14","author":"Garrison","year":"2023","journal-title":"Front. Physiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/ATVBAHA.119.313715","article-title":"Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension","volume":"40","author":"Bordenave","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1802308","DOI":"10.1183\/13993003.02308-2018","article-title":"CCR2\/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension","volume":"54","author":"Abid","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/ATVBAHA.120.314639","article-title":"Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients with Pulmonary Arterial Hypertension","volume":"41","author":"Zawia","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1152881","DOI":"10.3389\/fimmu.2023.1152881","article-title":"Role of macrophages in pulmonary arterial hypertension","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.00094706","article-title":"Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension","volume":"29","author":"Perros","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/art.41243","article-title":"Profibrotic Activation of Human Macrophages in Systemic Sclerosis","volume":"72","author":"Bhandari","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/art.42380","article-title":"Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma Patients","volume":"75","author":"Makinde","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","article-title":"Interleukin-6 overexpression induces pulmonary hypertension","volume":"104","author":"Steiner","year":"2009","journal-title":"Circ. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000111548","article-title":"Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension","volume":"75","author":"Ulrich","year":"2008","journal-title":"Respiration"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.rmed.2009.10.004","article-title":"T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension","volume":"104","author":"Austin","year":"2010","journal-title":"Respir. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"954007","DOI":"10.3389\/fimmu.2022.954007","article-title":"Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension","volume":"13","author":"Sanges","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1183\/09031936.00181410","article-title":"Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma","volume":"39","author":"Dib","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","article-title":"Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension","volume":"28","author":"Tamby","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Rol, N., Kurakula, K.B., Happe, C., Bogaard, H.J., and Goumans, M.J. (2018). TGF-beta and BMPR2 Signaling in PAH: Two Black Sheep in One Family. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092585"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Dannewitz Prosseda, S., Ali, M.K., and Spiekerkoetter, E. (2020). Novel Advances in Modifying BMPR2 Signaling in PAH. Genes, 12.","DOI":"10.3390\/genes12010008"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1164\/rccm.201408-1464OC","article-title":"Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-beta-dependent mouse model of pulmonary hypertension and in systemic sclerosis","volume":"191","author":"Gilbane","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2021.06.009","article-title":"Bone morphogenetic protein-7 inhibits endothelial-to-mesenchymal transition in primary human umbilical vein endothelial cells and mouse model of systemic sclerosis via Akt\/mTOR\/p70S6K pathway","volume":"103","author":"Shen","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","article-title":"TGF-beta signaling in health and disease","volume":"186","author":"Massague","year":"2023","journal-title":"Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor beta\u2014At the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the Treatment of Pulmonary Arterial Hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"156183","DOI":"10.1016\/j.cyto.2023.156183","article-title":"A comparative study of modulatory interaction between cytokines and apoptotic proteins among Scleroderma patients with and without pulmonary involvement","volume":"166","author":"Khadilkar","year":"2023","journal-title":"Cytokine"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Zaaroor Levy, M., Rabinowicz, N., Yamila Kohon, M., Shalom, A., Berl, A., Hornik-Lurie, T., Drucker, L., Tartakover Matalon, S., and Levy, Y. (2022). MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030629"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"106","DOI":"10.14797\/CBHS2234","article-title":"Novel Treatment Pathways in Pulmonary Arterial Hypertension","volume":"17","author":"Qaiser","year":"2021","journal-title":"Methodist DeBakey Cardiovasc. J."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ye, L., Wang, B., Xu, H., and Zhang, X. (2023). The Emerging Therapeutic Role of Prostaglandin E2 Signaling in Pulmonary Hypertension. Metabolites, 13.","DOI":"10.3390\/metabo13111152"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6736239","DOI":"10.1155\/2017\/6736239","article-title":"Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease","volume":"2017","author":"Kozij","year":"2017","journal-title":"Can. Respir. J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.amjcard.2017.06.012","article-title":"The Nitric Oxide Pathway in Pulmonary Vascular Disease","volume":"120","author":"Klinger","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.10","article-title":"Soluble guanylate cyclase: A new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"97","author":"Dasgupta","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"L1199","DOI":"10.1152\/ajplung.00092.2016","article-title":"Phosphorylation inactivation of endothelial nitric oxide synthesis in pulmonary arterial hypertension","volume":"310","author":"Ghosh","year":"2016","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/thx.52.12.1051","article-title":"Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension","volume":"52","author":"Kharitonov","year":"1997","journal-title":"Thorax"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"dev201786","DOI":"10.1242\/dev.201786","article-title":"Endothelin signaling in development","volume":"150","author":"Kanai","year":"2023","journal-title":"Development"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-022-02787-w","article-title":"The role of endothelin and RAS\/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: An updated review with therapeutic implications","volume":"24","author":"Rokni","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/ard.54.9.730","article-title":"Plasma endothelin-1 levels in patients with systemic sclerosis: Influence of pulmonary or systemic arterial hypertension","volume":"54","author":"Morelli","year":"1995","journal-title":"Ann. Rheum. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00296-017-3797-z","article-title":"Endothelin-1, alpha-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients","volume":"37","author":"Hajialilo","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12931-023-02559-3","article-title":"Prostaglandin and prostaglandin receptors: Present and future promising therapeutic targets for pulmonary arterial hypertension","volume":"24","author":"Zeng","year":"2023","journal-title":"Respir. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1124\/jpet.107.134221","article-title":"Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis","volume":"326","author":"Cathcart","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201001-0011OC","article-title":"Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension","volume":"182","author":"Falcetti","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc. and the Pulmonary Hypertension Association","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1017\/erm.2022.27","article-title":"The emerging role of NOTCH3 receptor signalling in human lung diseases","volume":"24","author":"Bodas","year":"2022","journal-title":"Expert. Rev. Mol. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5021\/ad.2019.31.4.365","article-title":"The Significance of NOTCH Pathway in the Development of Fibrosis in Systemic Sclerosis","volume":"31","author":"Zmorzynski","year":"2019","journal-title":"Ann. Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1161\/ATVBAHA.113.302062","article-title":"Soluble JAGGED1 inhibits pulmonary hypertension by attenuating notch signaling","volume":"33","author":"Xiao","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCRESAHA.118.313374","article-title":"Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1-Mediated Metabolic and Epigenetic Changes","volume":"124","author":"Miyagawa","year":"2019","journal-title":"Circ. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"H542","DOI":"10.1152\/ajpheart.00125.2021","article-title":"Notch2 suppression mimicking changes in human pulmonary hypertension modulates Notch1 and promotes endothelial cell proliferation","volume":"321","author":"Sahoo","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/nm.2021","article-title":"Notch3 signaling promotes the development of pulmonary arterial hypertension","volume":"15","author":"Li","year":"2009","journal-title":"Nat. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"106662","DOI":"10.1016\/j.isci.2023.106662","article-title":"Endothelial cell senescence exacerbates pulmonary hypertension by inducing juxtacrine Notch signaling in smooth muscle cells","volume":"26","author":"Ramadhiani","year":"2023","journal-title":"iScience"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1183\/13993003.00773-2015","article-title":"Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension","volume":"48","author":"Dabral","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard.2010.134742","article-title":"Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis","volume":"70","author":"Dees","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_147","first-page":"2233","article-title":"Functional Variants Increase Notch Signaling and Susceptibility for Systemic Sclerosis","volume":"74","author":"Kaundal","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1002\/art.27626","article-title":"Targeting ADAM-17\/notch signaling abrogates the development of systemic sclerosis in a murine model","volume":"62","author":"Kavian","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/art.30254","article-title":"Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis","volume":"63","author":"Dees","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.18632\/aging.202308","article-title":"MiR-16-5p suppresses myofibroblast activation in systemic sclerosis by inhibiting NOTCH signaling","volume":"13","author":"Yao","year":"2020","journal-title":"Aging"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1161\/01.RES.0000124300.76171.C9","article-title":"Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation","volume":"94","author":"Noseda","year":"2004","journal-title":"Circ. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1172\/JCI137558","article-title":"Hypoxia-inducible factor signaling in pulmonary hypertension","volume":"130","author":"Pullamsetti","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ebiom.2018.06.003","article-title":"IL-33 Initiates Vascular Remodelling in Hypoxic Pulmonary Hypertension by up-Regulating HIF-1alpha and VEGF Expression in Vascular Endothelial Cells","volume":"33","author":"Liu","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1073\/pnas.1602978113","article-title":"HIF2alpha-arginase axis is essential for the development of pulmonary hypertension","volume":"113","author":"Cowburn","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"L216","DOI":"10.1152\/ajplung.00538.2017","article-title":"Divergent changes of p53 in pulmonary arterial endothelial and smooth muscle cells involved in the development of pulmonary hypertension","volume":"316","author":"Wang","year":"2019","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41467-019-11500-6","article-title":"CD146-HIF-1\u03b1 hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension","volume":"10","author":"Luo","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Hu, C.J., Poth, J.M., Zhang, H., Flockton, A., Laux, A., Kumar, S., McKeon, B., Mouradian, G., Li, M., and Riddle, S. (2019). Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension. Eur. Respir. J., 54.","DOI":"10.1183\/13993003.00378-2019"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s13555-023-00952-w","article-title":"Hypoxia-Inducible Factor-1alpha (HIF-1alpha) as a Biomarker for Changes in Microcirculation in Individuals with Systemic Sclerosis","volume":"13","author":"Maciejewska","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Mao, J., Liu, J., Zhou, M., Wang, G., Xiong, X., and Deng, Y. (2022). Hypoxia-induced interstitial transformation of microvascular endothelial cells by mediating HIF-1alpha\/VEGF signaling in systemic sclerosis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263369"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"929289","DOI":"10.3389\/fimmu.2022.929289","article-title":"Intimate intertwining of the pathogenesis of hypoxia and systemic sclerosis: A transcriptome integration analysis","volume":"13","author":"He","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/1756-185X.13822","article-title":"Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity","volume":"23","author":"Takagi","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"201787","DOI":"10.1155\/2011\/201787","article-title":"Endothelin Receptor Antagonists for the Treatment of Raynaud\u2019s Phenomenon and Digital Ulcers in Systemic Sclerosis","volume":"2011","author":"Arefiev","year":"2011","journal-title":"Int. J. Rheumatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and Tadalafil Up-Front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Denton","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/rheumatology\/kep413","article-title":"Effect of the dual endothelin receptor antagonist bosentan on Raynaud\u2019s phenomenon secondary to systemic sclerosis: A double-blind prospective, randomized, placebo-controlled pilot study","volume":"49","author":"Nguyen","year":"2010","journal-title":"Rheumatology"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Castellvi, I., Simeon, C.P., Sarmiento, M., Casademont, J., Corominas, H., and Fonollosa, V. (2020). Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0243651"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients with Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Jin, Q., Chen, D., Zhang, X., Zhang, F., Zhong, D., Lin, D., Guan, L., Pan, W., Zhou, D., and Ge, J. (2023). Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061579"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00296-012-2466-5","article-title":"Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications","volume":"33","author":"Kumar","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: The placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): Randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2665-9913(23)00238-2","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): Open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial","volume":"5","author":"Distler","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: The impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"160055","DOI":"10.1183\/16000617.0055-2016","article-title":"Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience","volume":"26","author":"Sitbon","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"ref_182","first-page":"179","article-title":"Long-term treatment of scleroderma-related digital ulcers with iloprost: A cohort study","volume":"35","author":"Colaci","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.healun.2013.06.008","article-title":"One-year experience with intravenous treprostinil for pulmonary arterial hypertension","volume":"32","author":"Benza","year":"2013","journal-title":"J. Heart Lung Transplant."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: A post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1164\/rccm.202109-2174OC","article-title":"Vascular-Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling","volume":"207","author":"Yanagihara","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the Treatment of Pulmonary Arterial Hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13075-020-2141-2","article-title":"ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis\u2014A EUSTAR analysis","volume":"22","author":"Butikofer","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/MCP.0000000000000887","article-title":"Evolving nonvasodilator treatment options for pulmonary arterial hypertension","volume":"28","author":"Medrek","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3899\/jrheum.110765","article-title":"Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease","volume":"39","author":"Johnson","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4728\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:33:52Z","timestamp":1760106832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":193,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094728"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094728","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}